Bio-Rad Laboratories, Inc.
BIO
$241.07
-$12.08-4.77%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -83.33% | -304.67% | 514.71% | -86.32% | 456.68% |
| Total Depreciation and Amortization | 2.70% | 5.38% | 4.29% | 1.68% | 4.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 96.10% | 441.52% | -1,628.60% | 80.93% | -1,296.80% |
| Change in Net Operating Assets | -19.26% | -2,534.15% | 8,928.00% | -77.97% | 234.00% |
| Cash from Operations | 86.10% | 53.33% | 67.39% | -0.43% | -28.86% |
| Capital Expenditure | 14.43% | -1.54% | 8.72% | -22.06% | -12.53% |
| Sale of Property, Plant, and Equipment | -- | -151.04% | -12.31% | 69.23% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,386.21% | -88.90% | -144.82% | -81.96% | 91.65% |
| Cash from Investing | 106.73% | -142.31% | -485.64% | -210.52% | 38.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 50.00% | 72.85% | -4.24% | -1.72% | -73.91% |
| Issuance of Common Stock | -21.82% | -9.74% | 9.79% | -8.12% | 24.32% |
| Repurchase of Common Stock | -2,068.09% | 99.93% | -224.36% | 51.30% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 86.91% | -260.88% | 52.36% | -100.00% |
| Foreign Exchange rate Adjustments | -166.67% | 257.46% | -220.80% | 43.70% | 235.27% |
| Miscellaneous Cash Flow Adjustments | -- | -1,300.00% | 1,300.00% | -- | -- |
| Net Change in Cash | 13.27% | 244.01% | -93.41% | 64.83% | -1.87% |